Jacky Créquit

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

M. Pérol, C. Chouaïd, David Pérol et al. · Journal of Clinical Oncology · 2012 · 233 citations

Medicine, Oncology, Pharmacology +13

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Nathalie Baize, I. Monnet, Laurent Greillier et al. · The Lancet Oncology · 2020 · 153 citations

Medicine, Oncology, Pharmacology +13

Migratory bronchiolitis obliterans organizing pneumonia after unilateral radiation therapy for breast carcinoma

Bruno Crestani, M. Kambouchner, Paul Soler et al. · European Respiratory Journal · 1995 · 102 citations · Full text

Medicine, Oncology, Pathology +13

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

D. Debieuvre, Olivier Molinier, L. Falchero et al. · The Lancet Regional Health - Europe · 2022 · 76 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study

A. Vergnenègre, R. Corre, H. Bérard et al. · Journal of Thoracic Oncology · 2010 · 36 citations · Full text

Medicine, Oncology, Pharmacoeconomics +15